Correction

Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

Caroline M. Robb[1], Smit Kour[1], Jacob I. Contreras[1], Ekta Agarwal[1], Carter J. Barger[1], Sandeep Rana[1], Yogesh Sonawane[1], Beth K. Neilsen[1], Margaret Taylor[1], Smitha Kizhake[1], Rhishikesh N. Thakare[2], Sanjib Chowdhury[3], Jing Wang[1,4], Jennifer D. Black[1,4], Michael A. Hollingsworth[1,4], Michael G. Brattain[1,4,*] and Amarnath Natarajan[1,2,4]

[1]Eppley Institute for Research in Cancer, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA

[2]Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA

[3]Section of Gastroenterology, Department of Medicine, Boston University Medical Center, Boston, Massachusetts 02118, USA

[4]Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA

[*]Deceased

Published: *June 23, 2020*

This article has been corrected: The pRb blots in HCT116 and HT29 in Figure 3B were inadvertently duplicated during the assembly of the figure. The corrected Figure 3 is shown below. The authors declare that these corrections do not change the results or the conclusions of this paper.

Original article: Oncotarget. 2018; 9:5216–5232. https://doi.org/10.18632/oncotarget.23749



Figure 3: 20-223 inhibits the kinase activity of CDK5 and CDK2 *in vitro*. (**A**) Baseline expression of CDK2 and pRB (S807/811) (left), CDK5 and pFAK (S732) (right), in untreated CRC cells. (**B**) Representative western blots of target substrate pRB and pFAK phosphorylation levels in GEO (left), HCT116 (middle) and HT29 (right) cell lines after 6 hour incubation with 20-223. (**C**) Representative quantification of % inhibition of CDK2 and CDK5 kinase activity (based on substrate phosphorylation levels) in GEO cells found in Figure 3B. (**D**) Cell-based IC_{50} values generated from phosphorylation levels in Figure3B of CDK2 and CDK5 in three CRC cell lines.